1. Home
  2. MOS vs TGTX Comparison

MOS vs TGTX Comparison

Compare MOS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mosaic Company (The)

MOS

Mosaic Company (The)

HOLD

Current Price

$22.17

Market Cap

7.3B

Sector

Industrials

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.41

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOS
TGTX
Founded
1987
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
8.5B
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
MOS
TGTX
Price
$22.17
$55.41
Analyst Decision
Hold
Strong Buy
Analyst Count
16
5
Target Price
$31.94
$49.80
AVG Volume (30 Days)
8.7M
2.5M
Earning Date
05-11-2026
05-04-2026
Dividend Yield
3.82%
N/A
EPS Growth
209.09
1746.67
EPS
N/A
0.12
Revenue
$12,052,400,000.00
$2,785,000.00
Revenue This Year
$9.01
$49.08
Revenue Next Year
N/A
$26.69
P/E Ratio
N/A
$458.50
Revenue Growth
8.36
N/A
52 Week Low
$19.80
$25.37
52 Week High
$37.53
$59.30

Technical Indicators

Market Signals
Indicator
MOS
TGTX
Relative Strength Index (RSI) 50.91 59.33
Support Level $20.37 $28.57
Resistance Level $24.40 $58.34
Average True Range (ATR) 0.77 2.43
MACD 0.18 -0.62
Stochastic Oscillator 57.14 55.09

Price Performance

Historical Comparison
MOS
TGTX

About MOS Mosaic Company (The)

Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in the US and potash mines in Canada. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: